Hubbry Logo
5-HT7 receptor5-HT7 receptorMain
Open search
5-HT7 receptor
Community hub
5-HT7 receptor
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
5-HT7 receptor
5-HT7 receptor
5-HT7 receptor
View on Wikipedia
from Wikipedia
HTR7
Identifiers
AliasesHTR7, 5-HT7, 5-HT7 receptor, 5-hydroxytryptamine receptor 7
External IDsOMIM: 182137; MGI: 99841; HomoloGene: 20244; GeneCards: HTR7; OMA:HTR7 - orthologs
Orthologs
SpeciesHumanMouse
Entrez

3363

15566

Ensembl

ENSG00000148680

ENSMUSG00000024798

UniProt

P34969

P32304

RefSeq (mRNA)

NM_019860
NM_000872
NM_019859

RefSeq (protein)

NP_000863
NP_062873
NP_062874

Location (UCSC)Chr 10: 90.74 – 90.86 MbChr 19: 35.94 – 36.03 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

The 5-HT7 receptor is a member of the GPCR superfamily of cell surface receptors and is activated by the neurotransmitter serotonin (5-hydroxytryptamine, 5-HT).[5] The 5-HT7 receptor is coupled to Gs (stimulates the production of the intracellular signaling molecule cAMP)[6][7] and is expressed in a variety of human tissues, particularly in the brain, the gastrointestinal tract, and in various blood vessels.[7] This receptor has been a drug development target for the treatment of several clinical disorders.[8] The 5-HT7 receptor is encoded by the HTR7 gene, which in humans is transcribed into 3 different splice variants.[9]

Function

[edit]

When the 5-HT7 receptor is activated by serotonin, it sets off a cascade of events starting with release of the stimulatory G protein Gs from the GPCR complex. Gs in turn activates adenylate cyclase which increases intracellular levels of the second messenger cAMP.

The 5-HT7 receptor plays a role in smooth muscle relaxation within the vasculature and in the gastrointestinal tract.[5] The highest 5-HT7 receptor densities are in the thalamus and hypothalamus, and it is present at higher densities also in the hippocampus and cortex. The 5-HT7 receptor is involved in thermoregulation, circadian rhythm, learning and memory, and sleep. Peripheral 5-HT7 receptors are localized in enteric nerves; high levels of 5-HT7 receptor-expressing mucosal nerve fibers were observed in the colon of patients with irritable bowel syndrome. An essential role of 5-HT7 receptor in intestinal hyperalgesia was demonstrated in mouse models with visceral hypersensitivity, of which a novel 5-HT7 receptor antagonist administered perorally reduced intestinal pain levels.[10] It is also speculated that this receptor may be involved in mood regulation, suggesting that it may be a useful target in the treatment of depression.[11][12]

Variants

[edit]

Three splice variants have been identified in humans (designated h5-HT7(a), h5-HT7(b), and h5-HT7(d)), which encode receptors that differ in their carboxy terminals.[9] The h5-HT7(a) is the full length receptor (445 amino acids),[7] while the h5-HT7(b) is truncated at amino acid 432 due to alternative splice donor site. The h5-HT7(d) is a distinct isoform of the receptor: the retention of an exon cassette in the region encoding the carboxyl terminal results a 479-amino acid receptor with a c-terminus markedly different from the h5-HT7(a). A 5-HT7(c) splice variant is detectable in rat tissue but is not expressed in humans. Conversely, rats do not express a splice variant homologous to the h5-HT7(d), as the rat 5-HT7 gene lacks the exon necessary to encode this isoform.[9] Drug binding affinities are similar across the three human splice variants;[13] however, inverse agonist efficacies appear to differ between the splice variants.[14]

Discovery

[edit]

In 1983, evidence for a 5-HT1-like receptor was first found.[15] Ten years later, 5-HT7 receptor was cloned and characterized.[7] It has since become clear that the receptor described in 1983 is 5-HT7.[16]

Ligands

[edit]

Numerous orthosteric ligands of moderate to high affinity are known. Signaling biased ligands were discovered and developed in 2018.[17]

Agonists

[edit]

Agonists mimic the effects of the endogenous ligand, which is serotonin at the 5-HT7 receptor (↑cAMP).

Antagonists

[edit]

Neutral antagonists (also known as silent antagonists) bind the receptor and have no intrinsic activity but will block the activity of agonists or inverse agonists. Inverse agonists inhibit the constitutive activity of the receptor, producing functional effects opposite to those of agonists (at the 5-HT7 receptor: ↓cAMP).[29][30] Neutral antagonists and inverse agonists are typically referred to collectively as "antagonists" and, in the case of the 5-HT7 receptor, differentiation between neutral antagonists and inverse agonists is problematic due to differing levels of inverse agonist efficacy between receptor splice variants. For instance, mesulergine and metergoline are reported to be neutral antagonists at the h5-HT7(a) and h5-HT7(d) receptor isoforms but these drugs display marked inverse agonist effects at the h5-HT7(b) splice variant.[14]

Tetrahydroisoquinoline alkaloids found in peyote and related to mescaline have been found to act as potent inverse agonists of the serotonin 5-HT7 receptor.[40] These compounds include pellotine, anhalidine, anhalonidine, anhalamine, and N-methylanhalinine.[40]

Inactivating antagonists

[edit]

Inactivating antagonists are non-competitive antagonists that render the receptor persistently insensitive to agonist, which resembles receptor desensitization. Inactivation of the 5-HT7 receptor, however, does not arise from the classically described mechanisms of receptor desensitization via receptor phosphorylation, beta-arrestin recruitment, and receptor internalization.[41] Inactivating antagonists all likely interact with the 5-HT7 receptor in an irreversible/pseudo-irreversible manner, as is the case with [3H]risperidone.[42][43]

See also

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

5-HT7 receptor

View on Grokipedia
from Grokipedia
The 5-HT7 receptor is a G protein-coupled receptor (GPCR) belonging to the superfamily of class A receptors, specifically one of the 14 known subtypes of serotonin (5-hydroxytryptamine, 5-HT) receptors, which is activated by the neurotransmitter serotonin to mediate various physiological processes in the central nervous system (CNS) and periphery. Encoded by the HTR7 gene on human chromosome 10q23.31, resulting in multiple splice variants in humans (5-HT7a, 5-HT7b, and 5-HT7d), which encode proteins of 445, 432, and 479 amino acids, respectively, each featuring seven transmembrane domains and differing primarily in their C-terminal tails, which influence signaling efficiency and trafficking. Upon activation, the receptor primarily couples to the Gs protein family, stimulating adenylyl cyclase to increase intracellular cyclic AMP (cAMP) levels, and can also activate mitogen-activated protein kinase (MAPK) pathways such as ERK1/2 via protein kinase A (PKA) and Ras-dependent mechanisms. Widely distributed in the brain and peripheral tissues, the 5-HT7 receptor shows high expression in CNS regions including the , , hippocampus, cortex, and , as well as in peripheral sites such as vascular , , , and immune cells. Its physiological roles encompass regulation of circadian rhythms through modulation of activity, , learning and processes, mood stabilization, and ; peripherally, it contributes to relaxation in blood vessels and intestines, as well as and immune responses. Pharmacologically, it exhibits nanomolar affinity for serotonin (pKi ~7.0–8.0) and is targeted by agonists like 5-carboxamidotryptamine (5-CT) and 8-hydroxy-2-(di-n-propylamino) (8-OH-DPAT), while selective antagonists such as SB-269970 (pKi 8.9) and methiothepin provide tools for studying its functions. The 5-HT7 receptor has emerged as a promising therapeutic target due to its involvement in neuropsychiatric disorders, with antagonism showing antidepressant-like effects in preclinical models (e.g., forced swim and tail suspension tests) and potential benefits, possibly enhancing the efficacy of existing treatments like antidepressants. It is also implicated in (where blockade may reduce seizures), (via inhibition of meningeal ), (linked to responses), and pain modulation, though its dual pronociceptive and antinociceptive roles require further clarification. Ongoing research as of 2025 highlights its prospects in sleep disorders, neurodevelopmental conditions, acute stress-related cognitive deficits, and intestinal immune regulation, underscoring the need for selective ligands to harness its therapeutic potential without off-target effects on other serotonin receptors.

Molecular Properties

Gene and Isoforms

The HTR7 gene, which encodes the 5-HT7 receptor, is located on and spans approximately 117 kb, producing a primary that yields a 479-amino-acid protein in its longest isoform. Orthologs are highly conserved, with the mouse Htr7 situated on and encoding a 448-amino-acid protein, while the rat Htr7 resides on and also produces a 448-amino-acid protein. Alternative splicing of the human HTR7 gene generates three principal isoforms—5-HT7(a), 5-HT7(b), and 5-HT7(d)—that differ primarily in the length and composition of their C-terminal intracellular tails due to the inclusion or exclusion of specific exons. The 5-HT7(a) isoform consists of 445 amino acids, 5-HT7(b) has 432 amino acids (truncated by 13 residues relative to 5-HT7(a)), and 5-HT7(d) extends to 479 amino acids with an additional 34 residues at the C-terminus compared to 5-HT7(a). These variants exhibit no substantial differences in core pharmacological properties, such as ligand affinity or G-protein coupling, but the varying C-terminal tails may influence receptor trafficking to the plasma membrane and rates of agonist-induced desensitization or internalization. The 5-HT7 receptor demonstrates strong evolutionary conservation, particularly in its seven transmembrane domains, with sequence identities exceeding 90% among mammals, reflecting purifying selection that maintains its structural integrity across vertebrates. Known polymorphisms in HTR7, such as the intronic SNP rs7916403, have been linked to altered receptor transcript expression levels and associated phenotypes like event-related oscillations in the , potentially impacting serotonergic signaling efficiency.

Protein Structure

The 5-HT7 receptor is a class A (rhodopsin-like) (GPCR) encoded by the HTR7 on human chromosome 10q23.31. It exhibits the characteristic topology of this GPCR subclass, consisting of seven α-helical transmembrane domains (TM1–TM7) that traverse the , flanked by an extracellular N-terminal domain and an intracellular C-terminal tail. These helices are interconnected by three extracellular loops (ECL1–ECL3) and three intracellular loops (ICL1–ICL3), which contribute to binding, coupling, and receptor stability. The overall architecture positions the ligand-binding site within the transmembrane bundle, while the intracellular regions facilitate interactions with signaling effectors. The orthosteric binding pocket resides deep in the core of the seven-transmembrane helix bundle, primarily shaped by residues from TM3, TM5, and TM6. Serotonin engages this site through a conserved between its protonated amine and the of Asp^{3.32} (Asp129 in human 5-HT7) in TM3, anchoring the ligand's positively charged moiety. Additional stabilizing interactions involve π-π stacking between the ring of serotonin and aromatic residues in TM6, including Trp^{6.48}, Phe^{6.51}, and Phe^{6.52}, as well as hydrophobic contacts with residues in TM5. These features, resolved at near-atomic resolution in cryo-EM structures of the active 5-HT7 receptor bound to agonists like 5-carboxamidotryptamine (5-CT) in complex with Gs protein (PDB ID: 7XTC), highlight the conserved yet subtype-specific determinants of ligand recognition in serotonin receptors. Post-translational modifications modulate the receptor's trafficking, stability, and regulatory dynamics. N-linked glycosylation occurs at two consensus sites in the extracellular N-terminal domain (Asn5-Ser-Ser and Asn66-Ala-Ser), which are essential for proper folding, processing, and plasma membrane expression; of these sites impairs receptor function without altering binding affinity. The intracellular C-terminal tail, rich in serine and residues, serves as a substrate for by G protein-coupled receptor kinases (GRKs) following stimulation, promoting β-arrestin recruitment, desensitization, and internalization to terminate signaling.

Tissue Distribution

Central Nervous System

The 5-HT7 receptor exhibits heterogeneous expression throughout the central nervous system, with particularly high levels observed in the hippocampus, thalamus, hypothalamus, cortex, suprachiasmatic nucleus, and amygdala. Autoradiographic studies using radioligands such as [³H]mesulergine have demonstrated dense binding in regions including the centromedial thalamic nucleus, CA2 pyramidal layer of the hippocampus, dorsal raphe nucleus, and substantia nigra in human brain tissue. Moderate expression is noted in the raphe nuclei and cerebellum. Immunohistochemical analyses in rat brains further confirm this distribution, revealing 5-HT7 receptor immunoreactivity in neuronal populations of the cortex, hippocampus (including pyramidal and granule cells), thalamus, and hypothalamus. Within neural tissues, the 5-HT7 receptor is localized both pre- and postsynaptically on . Postsynaptic expression is prominent on hippocampal CA1 pyramidal cells, where activation increases neuronal excitability, as evidenced by electrophysiological recordings. In the , 5-HT7 receptors are expressed on , modulating serotonergic activity through inhibitory mechanisms. Similarly, in the basolateral , these receptors reside on local , enhancing inhibitory synaptic input to principal neurons in an activity-dependent manner. Such localization patterns have been corroborated by and functional assays in models. Species differences in 5-HT7 receptor density are evident, with autoradiographic data showing generally lower binding levels in compared to ; for instance, cortical densities are higher in rats and pigs than in humans, while expression is relatively elevated in humans. These variations are attributed to differences in receptor regulation and tissue architecture across , as quantified through comparative radioligand binding studies. Immunohistochemical patterns remain broadly similar between developing and adult brains, though staining intensity increases with maturity.

Peripheral Tissues

The 5-HT7 receptor is expressed in various peripheral tissues, particularly in cells of the vascular and gastrointestinal systems. In vascular , including the , , and mesenteric arteries, the receptor has been detected through RT-PCR and analyses, confirming its presence at both mRNA and protein levels. For instance, real-time RT-PCR revealed 5-HT7 mRNA in rat abdominal , while ting identified the protein in superior mesenteric artery homogenates. This localization in vascular supports its role in peripheral . In the , 5-HT7 receptor expression is prominent in the of the (), colon, and , as well as in enteric neurons. Studies using RT-PCR have demonstrated mRNA presence in these regions, with functional evidence from isolated tissues indicating localization that contributes to gut regulation. further confirms expression in intestinal , including lymphoid tissues. The receptor is also found in immune-related peripheral tissues such as the and , where RT-PCR detected 5-HT7 mRNA in rat lymphoid cells. In immune cells, including macrophages, T cells, and dendritic cells, expression has been verified by RT-PCR, , and , with protein detected in splenic T cells and monocytes. For example, analysis showed 5-HT7 protein in human T lymphocytes, upregulated under inflammatory conditions. Expression levels are lower in other organs, including the liver, kidney, and heart, based on Northern blot and RT-PCR data from human tissues. No significant sex- or age-related variations in peripheral 5-HT7 distribution have been consistently reported in available studies. Isoform variations may influence peripheral expression, but specific impacts remain under investigation.

Physiological Functions

Signal Transduction

The 5-HT7 receptor, a member of the (GPCR) superfamily, primarily couples to the stimulatory Gs upon activation by serotonin or agonists. This coupling facilitates the activation of (AC), an enzyme that catalyzes the conversion of ATP to (cAMP), thereby elevating intracellular cAMP levels. Increased cAMP concentrations serve as a second messenger that binds to and activates (PKA), which in turn phosphorylates downstream targets, including the cAMP response element-binding protein (CREB) at serine 133, promoting its transcriptional activity. Beyond gene regulation, the cAMP-PKA pathway modulates function, particularly enhancing the activity of hyperpolarization-activated cyclic nucleotide-gated (HCN) channels, also known as Ih channels. Direct binding of cAMP to the cyclic nucleotide-binding domain of HCN channels shifts their voltage dependence to more depolarized potentials and increases their conductance, thereby influencing neuronal excitability through a mixed Na+/+ inward current. In certain cellular contexts, the 5-HT7 receptor exhibits alternative coupling to G12/13 proteins, which activate the p115RhoGEF, leading to the downstream activation of the RhoA and subsequent cytoskeletal rearrangements. Receptor desensitization occurs through by G protein-coupled receptor kinases (GRKs), particularly GRK2 and GRK3, on serine and residues in the C-terminal tail, followed by recruitment of β-arrestins. This β-arrestin binding uncouples the receptor from G proteins, promotes clathrin-mediated internalization, and attenuates signaling.

Roles in Physiology

The 5-HT7 receptor, prominently expressed in the , contributes to the of circadian rhythms by modulating the activity of the , the primary circadian pacemaker. Endogenous serotonin acting on these receptors facilitates non-photic phase shifts in the , aiding in the synchronization of physiological processes to environmental light-dark cycles. This role is supported by studies showing that selective 5-HT7 agonists, such as 8-OH-DPAT, induce phase advances in locomotor activity rhythms in when administered during the subjective day. In , hypothalamic 5-HT7 receptors help maintain body temperature homeostasis. Activation of these receptors by serotonin or agonists induces in , demonstrating their involvement in central mechanisms independent of other serotonergic pathways like 5-HT1A or 5-HT3. mice lacking 5-HT7 receptors exhibit attenuated hypothermic responses to serotonin, underscoring the receptor's essential contribution to this process. The 5-HT7 receptor also participates in sleep architecture, particularly by promoting rapid eye movement (REM) sleep. Genetic ablation of the receptor in mice results in reduced REM sleep duration, especially during the light phase, indicating that tonic serotonergic signaling through 5-HT7 facilitates REM generation and maintenance. Within the central nervous system, 5-HT7 receptors modulate nociception and pain thresholds. Most preclinical studies indicate an antinociceptive effect by dampening sensory processing in spinal and supraspinal pathways, with receptor activation reducing responses to thermal and mechanical stimuli, though some evidence suggests dual pro- and antinociceptive roles requiring further research. Hippocampal 5-HT7 receptors play a critical role in learning and memory, particularly in processes dependent on the hippocampus such as spatial navigation and contextual . Receptor stimulation enhances (LTP) at CA1 synapses, a key cellular correlate of memory formation, thereby supporting cognitive functions like and maze learning. These effects highlight the receptor's contribution to underlying adaptive behaviors. In peripheral , 5-HT7 receptors mediate in vascular , leading to reduced and . This is evident in systemic serotonin administration, which lowers through 5-HT7-dependent relaxation of arteries and veins, particularly in skeletal muscle beds. Such actions contribute to the regulation of peripheral blood flow and cardiovascular tone. The receptor influences gastrointestinal motility via expression in the and . 5-HT7 activation promotes peristaltic reflexes in the intestine and gastric relaxation in the fundus, facilitating accommodation and coordinated propulsion of contents through the gut. This supports normal digestive function by enhancing excitatory to muscle layers. In immune modulation, 5-HT7 receptors on T lymphocytes regulate cellular responses, including proliferation. Serotonin signaling through these receptors provides an accessory stimulus that enhances T-cell and clonal expansion upon encounter, thereby fine-tuning adaptive immune responses. These effects are mediated by rapid of downstream signaling molecules like ZAP-70 and LAT, integrating serotonergic input into T-cell receptor pathways. Across these physiological roles, the 5-HT7 receptor primarily signals through Gs-protein coupling to elevate intracellular cAMP levels, which serves as a key second messenger in transducing its effects.

Pharmacology

Agonists

The primary endogenous of the 5-HT7 receptor is serotonin (5-hydroxytryptamine, 5-HT), which binds with moderate to high affinity (pKi 8.1–9.0) across , , , and guinea-pig homologs. Another , 5-carboxamidotryptamine (5-CT), a synthetic analog, exhibits even higher potency at the receptor (pKi 9.0–9.8), surpassing 5-HT in binding affinity. Selective synthetic have been developed to probe 5-HT7 receptor function, with notable examples including LP-211 and AS-19, both featuring arylpiperazine scaffolds. LP-211 acts as a potent with a Ki of 15 nM (pKi ≈7.8) and demonstrates 25-fold selectivity over the (Ki 379 nM). Similarly, AS-19 binds with a Ki of 0.6 nM (pKi ≈9.2) and shows high selectivity relative to , 5-HT1B, 5-HT1D, and other serotonin subtypes. Structure-activity relationship (SAR) studies highlight the importance of the arylpiperazine motif, where an optimal butyl linker chain and substitutions such as 2-methoxyphenyl on the aryl ring enhance affinity and selectivity for 5-HT7 over other receptors. Non-selective agonists like 8-OH-DPAT (pKi 6.3–7.5; partial/full agonist depending on species) and , primarily targeting 5-HT1B/1D receptors, also activate the 5-HT7 receptor but with lower potency (pKi 5.7–6.6), resulting in limited selectivity across serotonin receptor subtypes. Overall potency rankings among these agonists follow the order 5-CT > 5-HT > 8-OH-DPAT ≈ , underscoring the receptor's preference for tryptamine-like structures.

Antagonists

The 5-HT7 receptor competitively inhibit serotonin binding, thereby blocking receptor activation and downstream signaling. Selective , such as SB-269970, display high affinity for the human 5-HT7 receptor with a pKi of 8.9 and exhibit greater than 100-fold selectivity over other serotonin receptor subtypes, including 5-HT1A and 5-HT2A, though with some off-target affinity at 5-HT5A. Similarly, SB-258719 serves as a selective with a pKi of 7.5 at the human 5-HT7 receptor and at least 100-fold selectivity against other serotonergic receptors and D2 receptors. Recent developments include novel selective antagonists like MC-170073 and MC-230078 (developed as of 2023), which show high selectivity and are used to study peripheral functions such as intestinal immune responses. Non-selective antagonists also target the 5-HT7 receptor but interact with multiple G-protein-coupled receptors. Methiothepin, for example, has a pKi of 8.4 at the human 5-HT7 receptor and shows appreciable affinity for 5-HT1B, 5-HT2A, and D1/D2 receptors. Ritanserin binds with moderate affinity (pKi 7.62–7.64) but lacks selectivity, acting potently at 5-HT2A/2C receptors (pKi >8.5) and with weaker effects on α1-adrenergic and H1 receptors. Certain antagonists function as inverse agonists by suppressing the receptor's constitutive activity in overexpressed systems. Methiothepin and ritanserin act as full inverse agonists at the 5-HT7 receptor, reducing basal activity more effectively than neutral antagonists like SB-258719. SB-269970 also demonstrates properties in functional assays. Inactivating antagonists, including methiothepin and , produce prolonged blockade through irreversible or pseudo-irreversible binding mechanisms, potentially involving covalent interactions or extremely slow dissociation rates that outlast typical competitive antagonists. Structure-activity relationship studies highlight tetrahydroisoquinoline scaffolds as effective for 5-HT7 antagonism, particularly when linked via butyl chains to arylsulfonamide moieties, yielding compounds like DR-4004 with pKi values around 8.7 and good selectivity over 5-HT1A/2 subtypes, though some exhibit off-target D4 affinity. Aza-indole scaffolds, such as 7-azaindole derivatives in piperazine-linked structures (e.g., DR-4365, pKi 8.45), enhance binding through nitrogen substitution on the ring, improving metabolic stability but introducing potential off-target effects at 5-HT2C receptors.

Discovery and History

Initial Identification

The recognition of the 5-HT7 receptor emerged in the early from pharmacological binding studies that revealed heterogeneity among serotonin (5-HT) receptors in mammalian brain tissues. High-affinity binding sites for [3H]-5-HT were identified in regions such as the , displaying nanomolar affinity for 5-HT and 5-carboxamidotryptamine (5-CT) but not fully accounted for by known 5-HT1 or 5-HT2 subtypes. These sites suggested the existence of an additional 5-HT receptor population, prompting further investigation into receptor diversity beyond the established 5-HT1-like family. Distinction of this novel receptor from other 5-HT subtypes, particularly the 5-HT1-like receptors, was based on atypical pharmacological responses to . For instance, , a selective 5-HT2A/2C , failed to displace [3H]-LSD or [3H]-5-HT from these sites at concentrations that effectively blocked 5-HT2 receptors, while non-selective antagonists like methiothepin showed high affinity. This profile indicated a unique receptor not fitting the inhibitory Gi/o-coupled 5-HT1 class or the Gq-coupled 5-HT2 class, highlighting its independence within the GPCR superfamily. Early functional assays further supported the identification of this receptor as positively coupled to . In transfected cell lines expressing the receptor, 5-HT and 5-CT elicited dose-dependent elevations in intracellular cAMP levels, with values in the nanomolar range, confirming Gs protein mediation and distinguishing it from the cAMP-inhibitory 5-HT1 receptors. These responses were blocked by antagonists like and ritanserin at atypical potencies, reinforcing the receptor's unique signaling profile.

Key Developments

The cloning of the 5-HT7 receptor (HTR7) in 1993 marked a pivotal milestone in serotonin receptor research, achieved independently by multiple groups using homology-based strategies to other known 5-HT receptors. et al. identified the receptor through screening a placental cDNA library, revealing a positively coupled to adenylate cyclase, with expression confirming serotonin-mediated cAMP elevation in transfected COS-7 cells. Concurrently, Lovenberg et al. cloned the ortholog and extended findings to sequences, demonstrating high-affinity binding to 5-HT and structural similarities to 5-HT1 receptors, which facilitated its classification as a novel subtype. Ruat et al. further corroborated these results by isolating the from a , emphasizing its distinct pharmacological profile and widespread tissue distribution. In the mid- to late-, transfection studies in mammalian cell lines solidified the receptor's and signaling pathways. Expression in HEK293 and COS-7 cells confirmed G_s protein coupling, leading to robust increases in intracellular cAMP upon 5-HT stimulation, with values around 1-10 nM, distinguishing it from other 5-HT subtypes. These experiments also delineated affinities, such as high potency for 5-carboxamidotryptamine (5-CT) and 8-OH-DPAT, while revealing atypical responses to classical antagonists like , which bound with low affinity. Such studies built on initial binding assays from the early 1990s, confirming the receptor's identity and enabling functional validation across . The development of selective ligands around represented a breakthrough for precise pharmacological probing. SB-269970 emerged as the first highly selective 5-HT7 , exhibiting a pK_i of 8.9 at 5-HT7(a) receptors and over 100-fold selectivity against other 5-HT subtypes, , and adrenergic receptors; its tritiated form served as a radioligand for binding studies in native tissues. This tool, alongside early agonists like AS-19 (introduced shortly after), allowed dissection of receptor-specific effects, such as and modulation, previously confounded by non-selective compounds. Post-2010 advances have enhanced structural and functional insights into the 5-HT7 receptor. Homology models based on crystal structures of related serotonin receptors, such as 5-HT1B (PDB: 5V54, 2016) and 5-HT2B (PDB: 3OBZ, 2011), have illuminated ligand-binding pockets and activation mechanisms, predicting key residues like Ser5.42 for agonist interactions and aiding virtual screening for novel modulators. In the 2020s, research has elucidated the receptor's immunomodulatory roles, with 5-HT7 activation on dendritic cells promoting IL-6 and IL-8 secretion while suppressing pro-inflammatory IL-12, influencing T-cell differentiation and autoimmune responses.

Clinical Implications

Role in Disorders

The 5-HT7 receptor has been implicated in the of several neuropsychiatric disorders, particularly through dysregulation of its expression and signaling in key brain s. In models of depression, leads to upregulated 5-HT7 mRNA expression in the hippocampus and , contributing to depressive-like behaviors such as increased immobility in forced swim tests. Similarly, of the 5-HT7 receptor in the hippocampal CA1 promotes depressive-like phenotypes via matrix metalloproteinase-9 (MMP-9) signaling, as observed in mouse models and post-mortem analyses of human brains showing elevated receptor activity. For anxiety, preclinical evidence suggests involvement in anxiety-like behaviors, with antagonism reducing symptoms in models like the Vogel conflict test, indicating potential overactivity in pathological states, though expression changes are less consistently reported. In , 5-HT7 receptor mRNA is downregulated in the and hippocampal formation of affected individuals, correlating with cognitive deficits and hippocampal dysfunction, including impaired executive function and [long-term potentiation](/page/Long-term_p potentiation). In neurodegenerative conditions, the 5-HT7 receptor contributes to memory impairment and neuroinflammatory processes. In (AD), decreased HTR7 mRNA levels in the frontal cortex () are observed, correlating with hallucinations, while thalamic upregulation may exacerbate psychotic symptoms. This dysregulation impairs in hippocampal circuits, as evidenced by reduced long-term potentiation in AD models. In (MS), 5-HT7 receptor expression is increased on T lymphocytes in natalizumab-treated patients, promoting IL-10 release, an , and potentially modulating neuroinflammation in the . Peripherally, the 5-HT7 receptor plays a role in gastrointestinal disorders. In (IBS), particularly the constipation-predominant subtype, upregulated 5-HT7 receptor expression in the colon and enhances visceral hypersensitivity and alters motility, as shown in models where receptor activation promotes neurite outgrowth and signaling. In gastric cancer, 5-HT7 receptor agonism stimulates proliferation of cancer cells, including KATO-III lines and tissues, via apoptotic pathway inhibition, indicating its contribution to tumor growth and . The receptor is also associated with and disorders. In , 5-HT7 receptor facilitation in trigeminal ganglia and nucleus caudalis promotes (CGRP) release, exacerbating in animal models. For , receptor activation modulates descending inhibition but can contribute to hypersensitivity in states, with genetic or pharmacological alterations altering thresholds. Regarding disturbances, 5-HT7 receptor knockout in mice reduces rapid eye movement () duration, particularly during light periods, suggesting dysregulation disrupts circadian rhythms and architecture in disorders like or mood-related issues. Overall, these pathological roles highlight the 5-HT7 receptor's broad involvement in central and peripheral dysfunctions, often through altered expression or signaling that deviates from its normal physiological modulation of neuronal excitability and .

Therapeutic Potential

The 5-HT7 receptor has emerged as a promising target for mood and anxiety disorders, primarily through antagonism. Selective antagonists like SB-269970 have demonstrated antidepressant-like effects in models, reducing immobility in the forced swimming and tail suspension tests in mice at doses of 5-10 mg/kg, indicating potential efficacy against depression-like behaviors. Similarly, SB-269970 exhibits anxiolytic-like activity in rat models such as the elevated plus-maze and Vogel conflict tests at lower doses (0.5-1 mg/kg), without inducing motor impairments. These preclinical findings suggest that 5-HT7 receptor blockade could augment serotonergic therapies for affective disorders. Agonists targeting the 5-HT7 receptor show therapeutic promise for cognitive enhancement, particularly in stress-related impairments. In mouse models of repeated acute stress, the agonist AS19 (5 mg/kg) reversed memory deficits in novel object recognition and passive avoidance tasks by mitigating hippocampal , , and BDNF reductions. This neuroprotective effect highlights 5-HT7 activation as a strategy to restore cognitive function under stress conditions. In neurodegeneration, 5-HT7 modulation addresses memory deficits associated with (AD). Activation with AS19 improves hippocampal long-term potentiation and reduces in AD rat models, enhancing synaptic function and memory performance. Conversely, knockdown of 5-HT7 receptors in the ameliorates tau pathology-induced long-term potentiation deficits and impairments in transgenic mice, implicating receptor inhibition in mitigation. Preclinical evidence also supports 5-HT7 involvement in roles for (MS) and gut disorders. In MS, increased expression of 5-HT7 receptors on T lymphocytes promotes IL-10 release, an , suggesting receptor targeting could enhance immune regulation in preclinical models. For gut disorders like , 5-HT7 activation via the 5-HT/5-HT7R/ pathway in B cells reduces and histopathological damage in mouse models, as shown in 2024 studies. Additionally, 5-HT7 receptor expression on myeloid cells modulates acute and chronic severity in . Despite these advances, challenges persist in translating 5-HT7-targeted therapies to the clinic. As of 2025, no dedicated clinical trials for selective 5-HT7 ligands have advanced beyond preclinical stages, limiting human efficacy data. Promising dual-target compounds, such as 5-HT7 antagonists combined with inhibitors, exhibit antinociceptive effects in models alongside antidepressant activity in , offering multifunctional potential. Safety concerns include off-target effects due to 5-HT7 distribution in the CNS and periphery, while selectivity issues arise from structural similarities with other 5-HT receptors, necessitating refined design.

References

  1. https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=12
  2. https://pmc.ncbi.nlm.nih.gov/articles/PMC3031120/
  3. https://pmc.ncbi.nlm.nih.gov/articles/PMC2841472/
  4. https://www.sciencedirect.com/science/article/abs/pii/S0166432825004887
  5. https://journals.physiology.org/doi/10.1152/ajpgi.00299.2023
  6. https://www.ncbi.nlm.nih.gov/gene/3363
  7. https://www.ncbi.nlm.nih.gov/gene/15566
  8. https://www.uniprot.org/uniprotkb/P32305/entry
  9. https://rgd.mcw.edu/rgdweb/report/gene/main.html?id=71034
  10. https://pubmed.ncbi.nlm.nih.gov/9084407/
  11. https://pubmed.ncbi.nlm.nih.gov/19305739/
  12. https://pubmed.ncbi.nlm.nih.gov/20085376/
  13. https://pubmed.ncbi.nlm.nih.gov/9931439/
  14. https://pmc.ncbi.nlm.nih.gov/articles/PMC3139811/
  15. https://pubmed.ncbi.nlm.nih.gov/24736177/
  16. https://pmc.ncbi.nlm.nih.gov/articles/PMC10618075/
  17. https://pmc.ncbi.nlm.nih.gov/articles/PMC4181333/
  18. https://pmc.ncbi.nlm.nih.gov/articles/PMC1574165/
  19. https://pubmed.ncbi.nlm.nih.gov/12711351/
  20. https://pubmed.ncbi.nlm.nih.gov/14965246/
  21. https://pmc.ncbi.nlm.nih.gov/articles/PMC10497691/
  22. https://pubmed.ncbi.nlm.nih.gov/32736087/
  23. https://pmc.ncbi.nlm.nih.gov/articles/PMC4539517/
  24. https://www.sciencedirect.com/science/article/abs/pii/S0028390821003348
  25. https://pmc.ncbi.nlm.nih.gov/articles/PMC8460595/
  26. https://pmc.ncbi.nlm.nih.gov/articles/PMC3418156/
  27. https://molmed.biomedcentral.com/articles/10.1186/s10020-019-0126-x
  28. https://pmc.ncbi.nlm.nih.gov/articles/PMC4263172/
  29. https://pubmed.ncbi.nlm.nih.gov/10970681/
  30. https://pmc.ncbi.nlm.nih.gov/articles/PMC6938607/
  31. https://pubmed.ncbi.nlm.nih.gov/8226867/
  32. https://pubmed.ncbi.nlm.nih.gov/8394362/
  33. https://pmc.ncbi.nlm.nih.gov/articles/PMC4414735/
  34. https://pubmed.ncbi.nlm.nih.gov/9776378/
  35. https://www.jneurosci.org/content/35/11/4540
  36. https://www.jneurosci.org/content/25/34/7821
  37. https://pubmed.ncbi.nlm.nih.gov/16120784/
  38. https://pubmed.ncbi.nlm.nih.gov/12399592/
  39. https://pubmed.ncbi.nlm.nih.gov/14654097/
  40. https://www.pnas.org/doi/10.1073/pnas.0337340100
  41. https://pubmed.ncbi.nlm.nih.gov/24681431/
  42. https://pubmed.ncbi.nlm.nih.gov/36453491/
  43. https://pmc.ncbi.nlm.nih.gov/articles/PMC3385710/
  44. https://pmc.ncbi.nlm.nih.gov/articles/PMC3310936/
  45. https://www.frontiersin.org/journals/molecular-neuroscience/articles/10.3389/fnmol.2018.00353/full
  46. https://www.ahajournals.org/doi/10.1161/hyp.70.suppl_1.p319
  47. https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2021.679809/full
  48. https://journals.physiology.org/doi/full/10.1152/ajpgi.00496.2009
  49. https://www.gastrojournal.org/article/S0016-5085(05)01581-7/pdf
  50. https://journals.physiology.org/doi/full/10.1152/ajpgi.00012.2005
  51. https://ashpublications.org/blood/article/109/8/3139/23709/Serotonin-provides-an-accessory-signal-to-enhance
  52. https://pubmed.ncbi.nlm.nih.gov/15559250/
  53. https://pmc.ncbi.nlm.nih.gov/articles/PMC2910240/
  54. https://pmc.ncbi.nlm.nih.gov/articles/PMC3081126/
  55. https://www.pnas.org/doi/10.1073/pnas.90.18.8547
  56. https://pubmed.ncbi.nlm.nih.gov/10807680/
  57. https://www.sciencedirect.com/science/article/pii/S221112472200273X
  58. https://pubmed.ncbi.nlm.nih.gov/12165372/
  59. https://www.sciencedirect.com/science/article/pii/S019701862100231X
  60. https://www.sciencedirect.com/science/article/abs/pii/S0361923017300503
  61. https://pmc.ncbi.nlm.nih.gov/articles/PMC9599221/
  62. https://www.sciencedirect.com/science/article/pii/S1007437607600641
  63. https://pubmed.ncbi.nlm.nih.gov/35585132/
  64. https://pmc.ncbi.nlm.nih.gov/articles/PMC12147198/
  65. https://pubmed.ncbi.nlm.nih.gov/20236348/
  66. https://link.springer.com/article/10.1007/s40263-015-0236-0
  67. https://pubmed.ncbi.nlm.nih.gov/16828124/
  68. https://doi.org/10.1016/j.bbr.2025.115901
  69. https://pubmed.ncbi.nlm.nih.gov/28987281/
  70. https://pubmed.ncbi.nlm.nih.gov/32841723/
  71. https://www.sciencedirect.com/science/article/pii/S1874391924000174
  72. https://pubmed.ncbi.nlm.nih.gov/25072499/
Add your contribution
Related Hubs
User Avatar
No comments yet.